The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales
Eoghan McCarthy(Manchester Academic Health Science Centre), Benjamin Rhodes(University Hospitals Birmingham NHS Foundation Trust), Edward M Vital(University of Leeds), Anisur Rahman(University College London), David D’Cruz(St Thomas' Hospital), Emily Sutton(Manchester Academic Health Science Centre), Caroline Gordon(University of Birmingham), Ian N Bruce(University of Manchester), Stephanie Nesbit(Manchester Academic Health Science Centre), Peter Lanyon(Nottingham University Hospitals NHS Trust), Bridget Griffiths(Freeman Hospital), David Jayne(University of Cambridge), Neil McHugh(University of Bath), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Lee‐Suan Teh(Blackburn College), Chee‐Seng Yee(Unknown), Ben Parker(Manchester Royal Infirmary), Mohammed Akil, Asad Zoma(NHS Lanarkshire), David Isenberg(Regenerative Medicine Institute)
Cited by 4
Related Papers
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
|Arthritis & Rheumatism|2012|6.6k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k